ACH Accendra Health, Inc. Common Stock
NYSE · Health Care · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Jan 24, 2024ACH Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
ACH Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| April 1, 2010 | 3-for-2 | Forward |
| June 9, 1994 | 3-for-2 | Forward |
| March 23, 1993 | 3-for-2 | Forward |
| July 17, 1991 | 3-for-2 | Forward |
| June 1, 1988 | 3-for-2 | Forward |
| Sept. 3, 1985 | 3-for-2 | Forward |
| Nov. 1, 1982 | 2-for-1 | Forward |
About Accendra Health, Inc. Common Stock Company overview from Wikipedia
Accendra Health is a global healthcare company. It employs over 20,000 people in 70 countries. A Fortune 500 company, it was founded in 1882 in Richmond, Virginia, where it remains headquartered. The company has distribution, production, customer service and sales facilities located across the Asia Pacific region, Europe, Latin America, and North America. President and CEO Ed Pesicka joined Owens & Minor in March 2019.
History
Owens & Minor originally opened as a pharmacy company in downtown Richmond, Virginia in 1882, inside a historic building which still stands today. The company continued this business for over half a century until, in 1954, Gil Minor, Jr. bought out Bodeker Drug Company, a smaller operation in the same industry, changing the company name to Owens, Minor & Bodeker.
In 1966, the company acquired Virginia A&J Hospital Supply, adding medical and surgical distribution to its portfolio. By 1970, OMB had opened Cardinal Drug Centers, merchandising its products to independent drug companies, stocking shops with over 25,000 items within two years. Around this time, disposable items were distributed to hospitals for various medical procedures. G. Gilmer Minor III, a direct relation to the founder, became CEO in 1984. By 1988, Owens & Minor began trading on the New York Stock Exchange under the ticker OMI. It was around this time that revenues earned the company a Fortune 500 ranking.
By 1999, the company had refocused toward medical supply chain management. Throughout the 2000s, Owens & Minor acquired various medical distributors across the United States, notably the hospital distributor McKesson Medical-Surgical Inc., a business unit of McKesson, for $152.1 million, on September 30, 2006. In 2012, it entered the European market, opening offices in Spain, France, Germany, Poland, and the Czech Republic after the acquisition of Movianto Group. In 2014, the corporation acquired ArcRoyal, a privately held medical kit company based in Dublin, Ireland.
In 2018, it acquired Halyard Health’s Surgical & Infection Prevention business for $710 million, the largest acquisition in the company’s history. Halyard is a manufacturer of sterilization wrap, facial protection products, exam gloves, protective apparel, surgical drapes and surgical gowns.
In May 2022, Owens & Minor stated that 45 percent of the items it offers are in some way supply-constrained due to the 2021–2022 global supply chain crisis. The following month, the company broke ground in Morgantown, West Virginia for a 350,000 square-foot medical supplies and logistics center, to be completed in late 2023, which will include dedicated acute care medical distribution facilities and clinical supply capabilities.
In July 2024, the company announced it had agreed to acquire medical equipment firm Rotech Healthcare for $1.36 billion. However, the companies terminated the deal in June 2025, citing regulatory hurtles. As a result, the Owens & Minor paid Rotech an $80 million termination payment.
Personnel
On March 7, 2019 Edward A. Pesicka became president and CEO, then also joined the company's Board of Directors. Pesicka was a former executive at Thermo Fisher Scientific.
Richmond, Virginia center
In the fourth quarter of 2017, Owens & Minor opened a second office and customer service center in downtown Richmond, Virginia as part of a business rebranding strategy. The corporation also continued to work from its various offices across the United States.
Movianto
In 2018, the company’s Movianto subsidiary won a contract estimated at £10.5m a year to warehouse and distribute the UK government’s stock of emergency personal protection equipment (PPE) which had previously been managed by DHL.
Following a dispute over payment of rent, Movianto gained a UK High Court injunction in March 2019 to stop Industrial North West LLP, owner of the rented industrial property, from locking the gates and thereby preventing the company from conducting its business.
In 2020, Movianto was criticised as causing delays to the distribution of the UK government’s stockpile of PPE. Following news of shortages in hospitals, the British army was sent to Movianto’s warehouse to assist in the rapid deployment of PPE, with the Department of Health and Social Care contradicting the allegation. An investigation did establish, however, that Movianto had previously stored the equipment in a smoke-damaged warehouse that was found to contain asbestos.
On January 16, 2020, Owens & Minor announced its intention to sell its European logistics business, Movianto, to EHDH Holding Group (EHDH), a privately held French company providing healthcare logistics services to European markets, with the sale completed June 18, 2020.
Divest of P&HS - Rebrand Accendra Health, Inc.
On December 31 2025, Owens & Minor, Inc. announced the completion of the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to Platinum Equity and is renaming the publicly traded parent company Accendra Health, Inc.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Dec 14, 2021 | $0.00 | USD | ≈0.03% |
| Sep 14, 2021 | $0.00 | USD | ≈0.03% |
| Jun 14, 2021 | $0.00 | USD | ≈0.03% |
| Mar 12, 2021 | $0.00 | USD | ≈0.03% |
| Dec 14, 2020 | $0.00 | USD | ≈0.04% |
| Sep 14, 2020 | $0.00 | USD | ≈0.08% |
| Jun 12, 2020 | $0.00 | USD | ≈0.16% |
| Mar 13, 2020 | $0.00 | USD | ≈0.28% |
| Dec 13, 2019 | $0.00 | USD | ≈1.6% |
| Sep 13, 2019 | $0.00 | USD | ≈5.5% |
| Jun 13, 2019 | $0.00 | USD | ≈20.8% |
| Mar 14, 2019 | $0.00 | USD | ≈12.6% |
| Dec 14, 2018 | $0.08 | USD | ≈13.2% |
| Sep 14, 2018 | $0.26 | USD | ≈6.4% |
| Jun 14, 2018 | $0.26 | USD | ≈6.4% |
| Mar 14, 2018 | $0.26 | USD | ≈6.2% |
| Dec 14, 2017 | $0.26 | USD | ≈5.5% |
| Sep 14, 2017 | $0.26 | USD | ≈3.6% |
| Jun 13, 2017 | $0.26 | USD | ≈3.2% |
| Mar 13, 2017 | $0.26 | USD | ≈2.9% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 10, 2026 | $-0.19 | $-0.09 | -113.0% |
| March 31, 2026 | $-0.04 | $-0.10 | 60.9% | |
| Dec. 31, 2025 | $0.21 | $0.22 | -5.8% | |
| Sept. 30, 2025 | $0.25 | $0.23 | 6.7% | |
| June 30, 2025 | $0.26 | $0.28 | -6.3% | |
| March 31, 2025 | $0.23 | $0.20 | 16.6% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $290.99B | $298.89B | $203.99B | $190.22B | $180.35B | $181.02B | $144.85B | |
| Cost of Revenue | $259.70B | $264.17B | $188.52B | $179.28B | $167.11B | $166.29B | $133.70B | |
| Gross Profit | $31.28B | $34.72B | $15.47B | $10.93B | $13.24B | $14.73B | $11.15B | |
| R&D Expense | $4.81B | $2.42B | $1.47B | $941M | $627M | $498M | $169M | |
| SG&A Expense | $6.01B | $6.33B | $5.06B | $3.97B | $3.98B | $4.55B | · | |
| Operating Income | $16.39B | $18.67B | $7.60B | $6.21B | $6.82B | · | · | |
| Interest Expense | $3.83B | $4.51B | $4.99B | $4.38B | $4.69B | $4.83B | $4.76B | |
| Interest Income | $477M | $311M | $266M | $261M | $492M | $707M | $816M | |
| Pretax Income | $13.21B | $14.19B | $2.89B | $1.87B | $2.27B | $3.05B | $1.62B | |
| Income Tax | $2.37B | $2.87B | $641M | $632M | $826M | $644M | $404M | |
| Net Income | $4.19B | $5.76B | $862M | $596M | $709M | $1.41B | $366M | |
| EPS (Basic) | $0.24 | $0.33 | $0.03 | $0.02 | $0.03 | $0.09 | $0.02 | |
| EPS (Diluted) | $0.24 | $0.33 | $0.03 | $0.02 | · | · | · | |
| Shares (Basic) | 17,022,673 | 17,022,673 | 17,022,673 | 17,022,673 | 16,842,714 | 14,903,798,236 | 14,903,798,236 | |
| Shares (Diluted) | · | · | · | 17,022,672,951 | 16,842,713,738 | 14,903,798,236 | 14,903,798,236 | |
| EBITDA | $16.39B | $13.41B | $6.02B | · | · | · | · |
Balance Sheet
| Metric | Trend | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.82B | $19.68B | $9.67B | $7.78B | $19.13B | $27.85B | $23.85B | |
| Receivables | $5.87B | $7.11B | $9.31B | $7.42B | $8.10B | · | · | |
| Inventory | $24.71B | $21.64B | $19.86B | $19.52B | $20.46B | $20.55B | $17.93B | |
| Current Assets | $54.54B | $54.11B | $46.27B | $48.70B | $58.90B | $68.64B | $66.49B | |
| PP&E (Net) | $109.28B | $121.38B | $130.93B | $103.49B | $99.61B | $95.73B | $90.37B | |
| Goodwill | $3.50B | $3.51B | $3.51B | · | · | · | · | |
| Total Assets | $212.35B | $224.86B | $195.04B | $203.14B | $200.96B | $199.82B | $190.51B | |
| Current Liabilities | $62.37B | $61.92B | $62.63B | $69.20B | $74.84B | $90.34B | $83.18B | |
| Total Liabilities | $124.59B | $135.17B | $123.74B | $132.38B | $133.30B | $134.07B | $134.72B | |
| Retained Earnings | $10.09B | $6.81B | $-1.98B | $-2.21B | $-2.86B | $-3.33B | $-4.64B | |
| Stockholders' Equity | $54.40B | $60.48B | $54.45B | $54.67B | $52.42B | $39.69B | $38.17B |
Cash Flow
| Metric | Trend | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | $8.06B | $7.06B | $7.00B | |
| Operating Cash Flow | $27.75B | $35.16B | $19.42B | $12.51B | $13.02B | $13.21B | $11.61B | |
| CapEx | $4.42B | $3.19B | $10.33B | $9.05B | $6.75B | $8.89B | $6.33B | |
| Investing Cash Flow | $-3.42B | $-1.67B | $-3.31B | $-13.40B | $-5.53B | $-5.60B | $-2.63B | |
| Dividends Paid | $2.51B | $579M | $423M | $223M | $328M | $309M | $20M | |
| Financing Cash Flow | $-27.04B | $-23.41B | $-18.23B | $-10.47B | $-16.28B | $-3.39B | $-6.11B | |
| Free Cash Flow | $23.33B | $26.19B | $9.84B | $3.58B | · | · | · | |
| Levered FCF | $20.19B | $23.50B | $7.02B | $501M | · | · | · |
Profitability
| Metric | Trend | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 10.8% | 9.8% | 7.2% | 6.4% | · | · | · | |
| Operating Margin | 5.6% | 5.0% | 3.2% | · | · | · | · | |
| Net Margin | 1.4% | 1.9% | 0.40% | 0.45% | · | · | · | |
| Pretax Margin | 4.5% | 3.8% | 1.2% | 1.1% | · | · | · | |
| EBITDA Margin | 5.6% | 5.0% | 3.2% | · | · | · | · | |
| ROA | 1.9% | 2.6% | 0.37% | 0.42% | · | · | · | |
| ROE | 7.3% | 9.1% | 1.4% | 1.6% | · | · | · | |
| ROIC | 24.7% | 17.9% | 8.1% | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 0.7 | 0.7 | · | · | · | |
| Quick Ratio | 0.4 | 0.5 | 0.3 | 0.2 | · | · | · | |
| Interest Coverage | 4.3 | 3.8 | 1.6 | · | · | · | · |
Efficiency
| Metric | Trend | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.3 | 1.4 | 0.9 | 0.9 | · | · | · | |
| Inventory Turnover | 11.2 | 12.6 | 8.8 | 8.9 | · | · | · | |
| Receivables Turnover | 44.8 | 33.3 | 22.3 | 24.5 | · | · | · |
Per Share
| Metric | Trend | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue / Share | · | · | · | $11.17 | · | · | · | |
| Cash Flow / Share | · | · | · | $0.73 | · | · | · | |
| EPS (TTM) | $0.24 | $0.29 | $0.03 | $0.02 | · | · | · |
Valuation (TTM)
| Metric | Trend | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $290.99B | $269.75B | $185.99B | $190.22B | · | · | · | |
| Net Income TTM | $4.19B | $5.08B | $764M | $596M | · | · | · | |
| P/E | 81.7 | 152.1 | 901.7 | 235.0 | · | · | · | |
| Earnings Yield | 1.2% | 0.66% | 0.11% | 0.43% | · | · | · | |
| Payout Ratio | 60.0% | 9.1% | 48.1% | 26.2% | · | · | · | |
| Annual Payout | $2.51B | $461M | $356M | $223M | · | · | · |
Per Share
| Metric | Trend | Q4 2022 | Q4 2021 | Q4 2019 | Q4 2018 | Q4 2016 | Q4 2015 | Q4 2014 | Q4 2013 | Q4 2012 | Q4 2011 | Q4 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS (TTM) | · | $0.29 | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | Q4 2022 | Q4 2021 | Q4 2019 | Q4 2018 | Q4 2016 | Q4 2015 | Q4 2014 | Q4 2013 | Q4 2012 | Q4 2011 | Q4 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | $269.75B | · | · | $144.85B | $123.67B | · | · | · | · | · | |
| Net Income TTM | · | $5.08B | · | · | $366M | $130M | · | · | · | · | · | |
| P/E | · | 152.1 | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | · | 0.66% | · | · | · | · | · | · | · | · | · | |
| Annual Payout | · | $461M | · | · | $20M | $20M | · | · | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Revenue | $290.99B | $298.89B | $203.99B | $190.22B | $180.35B |
| Gross Margin % | 10.8% | 9.8% | 7.2% | 6.4% | · |
| Operating Margin % | 5.6% | 5.0% | 3.2% | · | · |
| Net Income | $4.19B | $5.76B | $862M | $596M | $709M |
| Diluted EPS | $0.24 | $0.33 | $0.03 | $0.02 | · |
| Metric | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 0.7 | 0.7 | · |
| Quick Ratio | 0.4 | 0.5 | 0.3 | 0.2 | · |
| Metric | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $23.33B | $26.19B | $9.84B | $3.58B | · |
Institutional owners (13F) 161 filers · $236.6M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 22 (-7 vs prior Q) | 21 (-25 vs prior Q) | 47 (+8 vs prior Q) | 45 (-7 vs prior Q) | -61K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Coliseum Capital Management, LLC | $44,804,760 | 13,100,807 | 18.94% | Shares |
| BlackRock, Inc. | $18,824,028 | 5,504,102 | 7.96% | Shares |
| VANGUARD GROUP INC | $17,691,199 | 6,318,285 | 7.48% | Shares |
| BANK OF AMERICA CORP /DE/ | $12,912,296 | 3,775,525 | 5.46% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $10,560,724 | 3,087,931 | 4.46% | Shares |
| D. E. Shaw & Co., Inc. | $10,538,412 | 3,081,407 | 4.45% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $9,877,158 | 2,888,058 | 4.17% | Shares |
| Invenomic Capital Management LP | $9,618,661 | 2,812,474 | 4.07% | Shares |
| MARSHALL WACE, LLP | $8,832,423 | 2,582,579 | 3.73% | Shares |
| PARADIGM CAPITAL MANAGEMENT INC/NY | $8,675,511 | 2,536,699 | 3.67% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6,945,870 | 2,030,956 | 2.94% | Shares |
| Dana Investment Advisors, Inc. | $6,650,556 | 1,944,607 | 2.81% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $6,408,062 | 1,873,127 | 2.71% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $5,609,358 | 1,640,163 | 2.37% | Shares |
| STATE STREET CORP | $5,475,974 | 1,601,162 | 2.31% | Shares |
| Connor, Clark & Lunn Investment Management Ltd. | $4,407,652 | 1,288,787 | 1.86% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $3,650,249 | 1,067,324 | 1.54% | Shares |
| GOLDMAN SACHS GROUP INC | $2,923,176 | 854,730 | 1.24% | Shares |
| TWO SIGMA INVESTMENTS, LP | $2,457,441 | 718,550 | 1.04% | Shares |
| NORTHERN TRUST CORP | $1,989,770 | 581,804 | 0.84% | Shares |
| WOLVERINE ASSET MANAGEMENT LLC | $1,942,847 | 568,084 | 0.82% | Shares |
| TUDOR INVESTMENT CORP ET AL | $1,939,995 | 567,250 | 0.82% | Shares |
| JANE STREET GROUP, LLC | $1,833,462 | 536,100 | 0.77% | Call option |
| Vanguard Global Advisers, LLC | $1,742,463 | 509,492 | 0.74% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $1,665,913 | 487,109 | 0.70% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,575,252 | 460,600 | 0.67% | Call option |
| TWO SIGMA ADVISERS, LP | $1,518,922 | 542,472 | 0.64% | Shares |
| BW Gestao de Investimentos Ltda. | $1,446,971 | 423,091 | 0.61% | Shares |
| CITADEL ADVISORS LLC | $1,321,919 | 386,526 | 0.56% | Shares |
| CITADEL ADVISORS LLC | $1,191,528 | 348,400 | 0.50% | Call option |
| Nebula Research & Development LLC | $1,115,105 | 122,539 | 0.47% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $1,109,492 | 324,413 | 0.47% | Shares |
| MORGAN STANLEY | $1,052,342 | 307,701 | 0.44% | Shares |
| Linden Thomas Advisory Services, LLC | $932,501 | 272,661 | 0.39% | Shares |
| Bank of New York Mellon Corp | $917,257 | 268,204 | 0.39% | Shares |
| Nuveen, LLC | $803,515 | 234,946 | 0.34% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $794,692 | 232,366 | 0.34% | Shares |
| Kennondale Capital Management LLC | $772,544 | 225,890 | 0.33% | Shares |
| STRS OHIO | $716,148 | 209,400 | 0.30% | Shares |
| MILLENNIUM MANAGEMENT LLC | $690,902 | 202,018 | 0.29% | Shares |
| Cubist Systematic Strategies, LLC | $593,424 | 123,630 | 0.25% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $546,095 | 159,677 | 0.23% | Shares |
| WELLS FARGO & COMPANY/MN | $542,754 | 158,700 | 0.23% | Shares |
| XTX Topco Ltd | $503,725 | 147,288 | 0.21% | Shares |
| ARISTEIA CAPITAL, L.L.C. | $447,391 | 130,816 | 0.19% | Shares |
| Invesco Ltd. | $446,351 | 130,512 | 0.19% | Shares |
| Man Group plc | $436,009 | 127,488 | 0.18% | Shares |
| RAYMOND JAMES FINANCIAL INC | $408,047 | 119,312 | 0.17% | Shares |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $362,520 | 106,000 | 0.15% | Shares |
| Allspring Global Investments Holdings, LLC | $356,879 | 99,687 | 0.15% | Shares |
ETF ownership Held by 18 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| VFVA · VANGUARD WELLINGTON FUND | 0.17% | 426,785 SH | Aug. 19, 2026 | Daily |
| QIDX · Spinnaker ETF Series | 0.11% | 14,310 NS | July 31, 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.02% | 62,833 SH | Aug. 19, 2026 | Daily |
| IWC · iShares Trust | 0.02% | 248,081 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 414,904 SH | Aug. 19, 2026 | Daily |
| DFSV · Dimensional ETF Trust | 0.01% | 233,042 NS | July 31, 2026 | N-PORT |
| RSSL · Global X Funds | 0.01% | 34,414 NS | July 31, 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0.00% | 134,690 NS | July 31, 2026 | N-PORT |
| IWM · iShares Trust | 0.00% | 1,902,936 SH | Sept. 11, 2026 | Daily |
| PRF · Invesco Exchange-Traded Fund Trust | 0.00% | 96,796 SH | Oct. 1, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.00% | 29,296 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.00% | 105,616 SH | Sept. 8, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 19,827 SH | Sept. 3, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 833,270 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 2,185,973 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 6,453 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.00% | 184,892 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 666,394 SH | Sept. 11, 2026 | Daily |
ACH Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
4 analysts · 2026-09-30Mean target $1.51 +199.4%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.